193 related articles for article (PubMed ID: 30877773)
1. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.
Bühler S; Jaeger VK; Adler S; Bannert B; Brümmerhoff C; Ciurea A; Distler O; Franz J; Gabay C; Hagenbuch N; Herzog C; Hasler P; Kling K; Kyburz D; Müller R; Nissen MJ; Siegrist CA; Villiger PM; Walker UA; Hatz C
Rheumatology (Oxford); 2019 Sep; 58(9):1585-1596. PubMed ID: 30877773
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
Han SB; Rhim JW; Shin HJ; Kim SY; Kim JH; Kim HH; Lee KY; Kim HM; Choi YY; Ma SH; Kim CS; Kim DH; Ahn DH; Kang JH
J Microbiol Immunol Infect; 2017 Apr; 50(2):207-213. PubMed ID: 26055693
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Diphtheria Booster Vaccination in Adolescents With Inflammatory Bowel Disease.
Dembiński Ł; Krzesiek E; Klincewicz B; Grzybowska-Chlebowczyk U; Demkow U; Banaszkiewicz A; Radzikowski A
Pediatr Infect Dis J; 2020 Mar; 39(3):244-246. PubMed ID: 32032309
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls.
Mischlinger J; Jaeger VK; Ciurea A; Gabay C; Hasler P; Mueller RB; Siegrist CA; Villiger P; Walker UA; Hatz C; Bühler S
Vaccine; 2022 Aug; 40(33):4897-4904. PubMed ID: 35810064
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of diphtheria-tetanus vaccine in adults.
Choi JH; Choo EJ; Huh A; Choi SM; Eom JS; Lee JS; Park SH; Kang JH
J Korean Med Sci; 2010 Dec; 25(12):1727-32. PubMed ID: 21165286
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity and immunogenicity of adult versus paediatric diphtheria and tetanus booster dose at 6 years of age.
Ciofi degli Atti ML; Salmaso S; Cotter B; Gallo G; Alfarone G; Pinto A; Bella A; von Hunolstein C
Vaccine; 2001 Oct; 20(1-2):74-9. PubMed ID: 11567748
[TBL] [Abstract][Full Text] [Related]
9. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
[TBL] [Abstract][Full Text] [Related]
10. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
11. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of diphtheria and tetanus vaccination in Gaza, Palestine.
Al Aswad IH; Shubair ME
East Mediterr Health J; 2009; 15(2):285-94. PubMed ID: 19554974
[TBL] [Abstract][Full Text] [Related]
14. The role of aluminium for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine.
Mark A; Granström M
Acta Paediatr; 1994 Feb; 83(2):159-63. PubMed ID: 8193494
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a single intramuscular dose of a tetanus-diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects.
Hong T; Chung YJ; Kim TY; Kim IH; Choe YK; Lee J; Jeon S; Han S; Yim DS
Hum Vaccin Immunother; 2015; 11(10):2440-5. PubMed ID: 26091286
[TBL] [Abstract][Full Text] [Related]
18. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients.
Enke BU; Bökenkamp A; Offner G; Bartmann P; Brodehl J
Transplantation; 1997 Jul; 64(2):237-41. PubMed ID: 9256180
[TBL] [Abstract][Full Text] [Related]
19. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
[TBL] [Abstract][Full Text] [Related]
20. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
